Medical cannabis for chronic pain was linked to reduced pain, anxiety, and improved sleep over 3 months | Research

The takeaway

Among 46 adults newly starting medical cannabis for chronic pain, ecological momentary assessment showed significant reductions in pain intensity, anxiety, depression, and improved sleep and quality of life over three months.

Pain researchers, medical cannabis clinicians, and patients considering cannabis for chronic pain.

Significant reductions in real-time pain intensity captured via 2,535 smartphone assessments

What the researchers found

Real-time EMA data (2,535 random + 705 daily assessments) showed significant reductions in momentary pain intensity after starting medical cannabis. Three-month follow-up surveys confirmed reduced pain, lower anxiety and depression, improved sleep, and better quality of life compared to baseline.

Why it matters

EMA captures real-time, in-the-moment data rather than relying on retrospective recall, providing a more ecologically valid picture of how medical cannabis affects daily pain and functioning.

The numbers in context

Participants: 46. Mean age: 55.7 years. Male: 52.2%. Random EMA assessments: 2,535. Daily EMA assessments: 705. Pain intensity reduction coefficient: -16.5. Follow-up: 3 months.

How the study worked

Prospective study of 46 adults (mean age 55.7) newly initiating medical cannabis for chronic pain. Used ecological momentary assessment (real-time smartphone surveys) for approximately 1 week pre-treatment and up to 3 weeks post-treatment, plus baseline and 3-month follow-up surveys.

What this study cannot tell us

No control group or randomization. Small sample size. Short EMA window (1-3 weeks). Self-selected population likely biased toward cannabis-positive attitudes. Potential expectancy effects.

How to read the evidence

Innovative EMA methodology strengthens momentary data quality, but uncontrolled design limits causal conclusions.

When this study was published

Published in 2021.

The bigger picture

While the improvements are encouraging, the lack of a control group means the observed benefits could reflect placebo effects, natural symptom fluctuation, or regression to the mean.

Questions still open

Would these benefits hold in a placebo-controlled design? Do the improvements persist beyond 3 months? Which cannabis formulations and dosing patterns produce the best outcomes?

Common questions

What is ecological momentary assessment?

A method using smartphone prompts to capture real-time data about pain, mood, and functioning in daily life, rather than relying on patients to remember how they felt weeks or months ago.

How much did pain improve with medical cannabis?

Momentary pain intensity showed statistically significant reductions during the EMA period, with continued improvements confirmed at the 3-month follow-up survey.

Read the original research

Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA).

Cannabis (Albuquerque, N.M.), 4(2), 69-83

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Yan; Jean Jacques, Jennifer; Li, Zhigang; Sibille, Kimberly T; Cook, Robert L. (2021). Health Outcomes among Adults Initiating Medical Cannabis for Chronic Pain: A 3-month Prospective Study Incorporating Ecological Momentary Assessment (EMA).. Cannabis (Albuquerque, N.M.), 4(2), 69-83. https://doi.org/10.26828/cannabis/2021.02.006